Feature | November 07, 2012

Kona Medical Announces Initiation of WAVE I Study of Renal Denervation Therapy for Hypertension

Kona Surround Sound Technology utilizes externally-delivered ultrasound to treat drug-resistant hypertension

November 7, 2012 — Kona Medical Inc. announced the initiation of the first clinical study of its device therapy for drug-resistant hypertension. The company is sponsoring the WAVE I clinical study to evaluate the safety and efficacy of its novel technology, and is now enrolling subjects at St. Vincent’s Hospital in Melbourne, Australia, under the direction of primary investigator Robert Whitbourn, M.D. The study design and initial results of WAVE I were presented on behalf of the investigators by Todd Brinton, M.D., at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) conference.

The Kona Surround Sound system utilizes focused ultrasound, delivered from outside the body, to treat the nerves leading to and from the kidney. The therapy of renal denervation has been shown in other studies to lead to significant and lasting reductions in high blood pressure. Unlike other renal denervation methods, which rely on a catheter emitting therapeutic energy through the wall of the renal artery to affect the renal nerves, Kona’s Surround Sound technology uses a novel method of treating the nerves from outside the patient. A transducer positioned outside the body delivers targeted ultrasound energy that “surrounds” the artery and treats the nerves located in the vicinity of the vessel. By creating a focused energy field around the outside of the artery, the Kona system may result in a more complete and effective ablation in a way that does not impact the walls of the artery.

“Renal denervation is becoming one of the fastest-growing interventional therapies,” said Whitbourn. “The Kona system has the potential to further improve clinical results, and may also lead to improved access to renal denervation therapy. We are pleased to be participating in the evaluation of the Kona system and anticipate reporting complete study results next spring.”

“Initiation of the WAVE I study is an important milestone in the development of therapies for hypertension,” added Michael Gertner, M.D., founder and CEO of Kona Medical. “Ultrasound has inherent advantages as an energy source for ablation, and we believe that external delivery of ultrasound energy better addresses the variability of the location of renal nerves and may lead to better outcomes. Importantly, focused external ultrasound also can enable a system that is entirely noninvasive. This could greatly expand access to renal denervation therapy, and would offer a more patient-friendly alternative for the tens of millions of people who suffer from drug-resistant hypertension.”

Kona Medical’s technology is investigational and is not yet for sale or approved in the United States.

For more information: www.konamedical.com

Related Content

Trial Data Shows Positive Predictive Results for Boston Scientific HeartLogic Heart Failure Diagnostic
News | Heart Failure| October 20, 2017
October 20, 2017 — Boston Scientific announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart F
Cardiovascular Risk Significantly Higher in Women With Fatty Liver Disease
News | Womens Healthcare| October 20, 2017
Nonalcoholic fatty liver disease (NAFLD) is associated with significantly higher risk of subsequent cardiovascular...
Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
MRI May Predict Neurological Outcomes for Cardiac Arrest Survivors
News | Sudden Cardiac Arrest| October 18, 2017
Magnetic resonance imaging (MRI)-based measurements of the functional connections in the brain can help predict long-...
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
Overlay Init